Complete financial analysis of Poseida Therapeutics, Inc. (PSTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Poseida Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Cohen & Company Inc. (COHN) Income Statement Analysis – Financial Results
- United Internet AG (UTDI.SW) Income Statement Analysis – Financial Results
- For The Earth Corp. (FTEG) Income Statement Analysis – Financial Results
- Investeringsforeningen Sydinvest – Danmark Indeks Kl (SYIDKI.CO) Income Statement Analysis – Financial Results
- The Bombay Burmah Trading Corporation, Limited (BBTC.NS) Income Statement Analysis – Financial Results
Poseida Therapeutics, Inc. (PSTX)
About Poseida Therapeutics, Inc.
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 64.70M | 130.36M | 31.24K | 0.00 | 0.00 | 0.00 | 2.99M | 9.77M |
| Cost of Revenue | 156.77M | 5.17M | 4.55M | 2.59M | 1.19M | 689.00K | 0.00 | 0.00 |
| Gross Profit | -92.07M | 125.19M | -4.52M | -2.59M | -1.19M | -689.00K | 2.99M | 9.77M |
| Gross Profit Ratio | -142.29% | 96.03% | -14,472.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% |
| Research & Development | 156.77M | 152.90M | 136.73K | 103.52K | 60.39M | 30.88M | 19.10M | 9.86M |
| General & Administrative | 37.44M | 37.54M | 35.92K | 23.03K | 18.46M | 9.67M | 5.48M | 5.35M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -220.00K |
| SG&A | 37.44M | 37.54M | 35.92K | 23.03K | 18.46M | 9.67M | 5.48M | 5.13M |
| Other Expenses | 0.00 | 2.86M | 19.80K | 280.00 | 2.56M | -821.00K | 37.00K | 0.00 |
| Operating Expenses | 194.21M | 190.44M | 172.65K | 126.55K | 78.85M | 40.56M | 24.58M | 15.00M |
| Cost & Expenses | 179.35M | 190.44M | 172.65K | 126.55K | 78.85M | 40.56M | 24.58M | 15.22M |
| Interest Income | 0.00 | 6.37M | 3.36M | 3.51M | 1.55M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 8.67M | 6.37M | 3.36K | 3.51K | 3.55M | 1.80M | 558.00K | 0.00 |
| Depreciation & Amortization | 5.61M | 5.17M | 4.55M | 2.59M | 1.19M | 689.00K | 676.00K | 220.00K |
| EBITDA | -109.04M | -54.77M | -117.06M | -145.48M | -91.68M | -45.12M | -20.88M | -5.12M |
| EBITDA Ratio | -168.52% | -43.79% | -389.32% | 0.00% | 0.00% | 0.00% | -699.50% | -53.53% |
| Operating Income | -129.50M | -59.95M | -141.41K | -126.55K | -85.53M | -41.99M | -19.67M | -5.45M |
| Operating Income Ratio | -200.15% | -45.98% | -452.69% | 0.00% | 0.00% | 0.00% | -658.89% | -55.78% |
| Total Other Income/Expenses | 6.18M | -3.51M | 16.44M | -129.65M | -7.68M | -2.62M | 1.40M | 109.00K |
| Income Before Tax | -123.32M | -63.46M | -124.97K | -129.78K | -86.53M | -44.61M | -20.19M | -5.34M |
| Income Before Tax Ratio | -190.60% | -48.68% | -400.07% | 0.00% | 0.00% | 0.00% | -676.35% | -54.67% |
| Income Tax Expense | 107.00K | 544.00K | -4.53M | -2.58M | 6.11M | -202.00K | -527.00K | -765.00K |
| Net Income | -123.43M | -64.00M | 4.40M | 2.45M | -92.64M | -44.40M | -19.66M | -4.58M |
| Net Income Ratio | -190.76% | -49.10% | 14,097.81% | 0.00% | 0.00% | 0.00% | -658.69% | -46.84% |
| EPS | -1.37 | -0.89 | 0.07 | 0.07 | -2.33 | -1.24 | -0.49 | -0.08 |
| EPS Diluted | -1.37 | -0.89 | 0.07 | 0.07 | -2.33 | -1.24 | -0.49 | -0.08 |
| Weighted Avg Shares Out | 90.19M | 71.91M | 62.18M | 36.00M | 39.73M | 35.93M | 39.73M | 59.32M |
| Weighted Avg Shares Out (Dil) | 90.19M | 71.95M | 62.24M | 36.00M | 39.73M | 35.93M | 39.73M | 59.32M |
What Makes Poseida Therapeutics, Inc. (PSTX) a New Buy Stock
Poseida Therapeutics, Inc. (PSTX) Reports Q1 Loss, Tops Revenue Estimates
Nutcracker Therapeutics appoints Cynthia Collins, biopharma veteran and former Editas Medicine CEO, to board of directors
Poseida Therapeutics, Inc. (PSTX) Reports Q4 Loss, Misses Revenue Estimates
Poseida Therapeutics to Present at H.C. Wainwright Cell Therapy Virtual Conference
Poseida Therapeutics: New Allogeneic Therapies, Leveraging Non-Viral Engineering
Poseida Therapeutics, Inc. (PSTX) is on the Move, Here's Why the Trend Could be Sustainable
Recent Price Trend in Poseida Therapeutics, Inc. (PSTX) is Your Friend, Here's Why
Poseida Therapeutics, Inc. (PSTX) Is a Great Choice for 'Trend' Investors, Here's Why
Poseida Therapeutics to Present Early Data from Phase 1 Trials of P-MUC1C-ALLO1 and P-BCMA-ALLO1 at ESMO Immuno-Oncology 2022 Annual Congress
Source: https://incomestatements.info
Category: Stock Reports